Forensic Analysis · Industrials / Manufacturing / Defense · as of Sep 1, 2026
Neovolta Inc. (NEOV)
A forensic read on Neovolta Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-13.2
Distress distance
Clean
Earnings quality
4
Forensic signals
-173.0%
ROE
218.6%
Revenue growth
The financial-health reading above compares this company's equity at BOOK value, not at what the market currently pays for it — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Neovolta Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -13.2, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-73.0%
FY2025
Return on invested capital.Return on invested capital is -73.0% in the latest fiscal year and rising from -194% — well below its ~9% cost of capital, and it has been across FY2022–FY2025, so reinvested dollars have not been earning their keep.
+17.8%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +63% over the last 3 years to FY2025 (+17.8%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~17.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~39%.
+26.6%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +26.6% relative to their own average in FY2025 — scaled by NOA itself, not by total assets, which is what the Forensic Screens card's own accrual row divides by. Accruals are building sharply, and much of it is accounted for. The build is led by receivables up +65% against revenue +219% and inventory up +20% against +224% in cost of sales. That build tracks a +219% revenue year: net operating assets grew +31% and receivables +65%, so the balance sheet is carrying more volume rather than getting heavier per dollar of sales — the accrual build is funding demand the company is shipping, not earnings running ahead of collection. A cash-flow measure on the same base disagrees: reported earnings ran behind operating cash by 15% of net operating assets, against an accruals ratio of 26.6%. The two are computed differently: the accruals ratio is the change in net operating assets over average net operating assets, while the cash-flow figure is net income less operating cash flow over that same average. Read them as two results, not one.
25% of rev
Key fundamentals
Latest Revenue$8.4M
Revenue Growth YoY+218.6%
Revenue CAGR (3yr)+23.5%
Net Margin-59.7%
Return on Equity-173.0%
Debt / Equity0.89x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Neovolta Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 1, 2026. Forensic signals flag probability, not certainty.
Neovolta Inc. (NEOV) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
FY2025
Stock-based comp load.Stock-based compensation ran 25% of revenue in FY2025 — about $0.06 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 20.2% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.